05:07 PM EST, 11/04/2025 (MT Newswires) -- PTC Therapeutics ( PTCT ) reported Q3 earnings late Tuesday of $0.20 per diluted share, swinging from a loss of $1.39 a year earlier.

Analysts polled by FactSet expected a loss of $1.13.

Revenue for the three months ended Sept. 30 was $211 million, up from $196.8 million a year earlier.

Analysts surveyed by FactSet expected $174.1 million.

The company now expects full-year 2025 revenue of $750 million to $800 million, revised from $650 million to $800 million earlier. Analysts expect $1.73 billion, if comparable.